AstraZeneca Receives Six Months Pediatric Exclusivity Patent Extension for ARIMIDEX(R
 

AstraZeneca (NYSE:AZN) today announced that the United States (US) Food and Drug Administration (FDA) has granted an additional six-month period of exclusivity to market ARIMIDEX(R) (anastrozole) for its licensed breast cancer indications until June 2010.

More...